Angiogenesis 2022 – CANDELA trial: high dose aflibercept for neovascular AMD
David Xu, MD Vitreoretinal Surgery Wills Eye Hospital Dr. David Brown presented the one-year results of the phase 2, randomized, single-masked study of high dose aflibercept for neovascular age-related macular…